Saturday 17 October 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
85.81
2.05
−2.33%
Follow SOLV
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
9.39 | 7.95 | 8.87 | 8.35 |
+8 more quarters Free account |
P/S ratio |
1.60 | 1.38 | 1.66 | 1.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 254.48 | |
P/Operating CF |
58.70 | (60.19) | 145.22 | 167.42 | |
P/B ratio |
2.78 | 2.29 | 2.73 | 2.55 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.19 | 1.95 | 2.17 | 1.94 | |
EV/EBITDA |
7.05 | 6.18 | 6.76 | 6.01 | |
EV/Operating CF |
87.11 | 106.63 | 48.92 | 33.10 | |
EV/FCF |
(154.29) | (79.32) | (1,805.27) | 326.38 | |
Quick Ratio |
0.50 | 0.52 | 0.66 | 0.96 | |
Current Ratio |
1.02 | 1.07 | 1.23 | 1.50 | |
Net Debt/EBITDA |
15.55 | 21.98 | 17.18 | 1.93 | |
Debt/Assets |
37.11% | 37.50% | 35.22% | 36.76% | |
Debt/Equity |
1.10 | 1.06 | 1.00 | 1.03 | |
Asset Turnover |
0.57 | 0.58 | 0.58 | 0.59 | |
Operating CF/Net income |
2.47 | (14.54) | 1.51 | 0.06 | |
Capex/Depreciation |
(0.62) | (0.62) | (0.54) | (0.80) | |
Interest Coverage |
2.83 | 1.29 | 2.45 | 18.99 | |
Research and Development Expense of Revenue |
8.06% | 9.42% | 8.71% | 8.73% | |
Selling, General and Administrative Expense of Revenue |
41.96% | 41.21% | 37.99% | 37.21% | |
Intangible Assets out of Total Assets |
0.56 | 0.58 | 0.58 | 0.54 | |
Share Based Compensation of Revenue |
1.72% | 2.54% | 1.85% | 1.96% | |
Graham Net Nets |
(0.43) | (0.49) | (0.39) | (0.36) | |
Graham Number |
71.69 | 72.60 | 76.34 | 75.00 | |
Earnings Yield |
10.65% | 12.57% | 11.27% | 11.97% | |
Free Cash Flow Yield |
(0.89%) | (1.78%) | (0.07%) | 0.39% | |
Revenue per Share |
12.79 | 11.52 | 11.48 | 12.03 | |
Operating CF per Share |
1.31 | (1.08) | 0.55 | 0.44 | |
Capex per Share |
(0.48) | (0.48) | (0.36) | (0.56) | |
Free Cash Flow per Share |
0.83 | (1.57) | 0.18 | (0.12) | |
Cash per Share |
2.33 | 3.22 | 5.04 | 9.42 | |
Shareholders Equity per Share |
27.79 | 28.52 | 29.00 | 28.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.79 | 28.52 | 29.00 | 28.61 | |
Free Cash Flow |
144.00 | (273.00) | 32.00 | (21.00) | |
Working Capital |
78.00 | 237.00 | 723.00 | 1,469.00 | |
Capital Expenditures |
(83.00) | (84.00) | (63.00) | (97.00) | |
Net Current Asset Value |
(5,702.00) | (5,545.00) | (5,386.00) | (4,580.00) | |
EV/EBIT |
8.77 | 7.63 | 8.28 | 7.44 | |
Capex to Sales |
0.04 | 0.04 | 0.03 | 0.05 | |
Price to Operating Income |
6.42 | 5.39 | 6.33 | 5.80 | |
| Other line items | |||||
Average Receivables |
1,343.50 | 1,145.50 | 1,206.50 | 1,251.50 | |
Average Payables |
672.00 | 651.50 | 652.50 | 614.50 | |
Average Inventory |
1,001.00 | 977.50 | 1,015.50 | 1,001.00 | |
Average Assets |
14,658.50 | 14,312.00 | 14,375.50 | 14,359.00 | |
Average Common Equity |
4,222.00 | 4,116.00 | 4,004.50 | 4,089.00 |
Columns are period end dates